Article
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
University Chidren's Hospital Zurich, Department of Oncology, Zurich, Switzerland.
Journal of Pediatric Hematology/Oncology (impact factor:
1.16).
05/2003;
25(4):327-9.
pp.327-9
Source: PubMed
-
Citations (0)
- Cited In (4)
-
Article: A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
[show abstract] [hide abstract]
ABSTRACT: We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.Haematologica 09/2006; 91(8):1105-8. · 6.42 Impact Factor -
Article: Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
[show abstract] [hide abstract]
ABSTRACT: We are reporting on a 14-year-old boy with a very early relapse of pre-B acute lymphoblastic leukemia (ALL) and anaplastic astrocytoma WHO degrees III; the astrocytoma was subtotally resected and subsequently treated with irradiation and chemotherapy. The leukemic relapse was refractory to the administered salvage therapy. Therefore, treatment with the human anti-CD20 monoclonal antibody (MoAb) IDEC-C2B8 (rituximab) was initiated. After a small fraction of the standard dose (375 mg/m(2)) had been administered, the infusion had to be interrupted because of an acute attack of pain in the lumbar region. Two days later, after resumption of the therapy, he developed a fatal course of systemic inflammatory response syndrome (SIRS) and died, possibly due to uncontrollable cytokine release syndrome associated with sepsis. The fatal course will be discussed based on a review of the literature.Haematologica 07/2006; 91(6 Suppl):ECR23. · 6.42 Impact Factor -
Article: Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
[show abstract] [hide abstract]
ABSTRACT: We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.Haematologica 03/2006; 91(2):272-3. · 6.42 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
1 year
12-year old boy
4 treatments
85% event-free survival
bone marrow
central nervous system
chemotherapy
childhood acute lymphoblastic leukemia
children
CNS
CNS remission
complete clinical
complete morphologic remission
intensive chemotherapy yields
isolated CNS relapse
primary chemotherapy
Rituximab
single agent
